国家医保局等部门印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新 药品目录》，自2026年1月1日起正式执行。 国家医保局成立以来医保药品目录已调整8次，本次医保药品目录调整新增114种药品，其中50种为1类 创新药。首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有社会关注度较高的阿 尔茨海默病治疗药品。 恒生医药ETF（159892）聚焦创新药产业，在港交所18A制度优势下覆盖众多创新标的（百济神州、信 达生物、康方生物等），有望受益于医保目录的更新和美联储降息。 （文章来源：每日经济新闻） 具体来看，复星医药的芦沃美替尼片进入2025年医保目录，北海康成的注射用维拉苷酶β进入商保创新 药目录。同时，5款CAR-T药进入商保创新药目录，分别是复星凯瑞的阿基仑赛注射液、药明巨诺的瑞 基奥仑赛注射液、合源生物的纳基奥仑赛注射液、驯鹿生物的伊基奥仑赛注射液、科济药业的泽沃基奥 仑赛注射液。 从药企角度来看，纳入医保+商保的创新药大多处于放量初期，随着政策红利释放，纳入医保、商保目 录的创新药有望快速放量。商保的逐步推广也有望增加创新药费用的支付来源，促进创新药在支付 ...

说完昨天晚上的消息面，接下来我们继续聊市场，那今天市场到底会怎么走？首先在这里面说一下我的 看法，我认为在周末利好的影响之下，今天市场出现高开的概率比较高，但是注意一点，如果今天市场 出现明显大幅高开的话，那么要注意点大幅高开之后呢市场会有回踩动作，只有扛住早盘半小时到一小 时的回踩，那么市场才算真正稳得住，才有机会走出新的上涨行情。而且也不能因为周末两天给很多的 利好消息，大家情绪上就太乐观。我这里面不是看空市场，我强调一点是在于一方面利好消息出来之后 情绪上会有反馈，但是最终决定于市场的是资金到底认可不认可，资金真正认可了，市场才能够走出新 的上涨走势，所以这才是核心点。所以早盘大家要注意几个信号，第一个大幅高开之后回踩动作回踩幅 度不能超过50%，最好是在50%以上，如果超过50%的话就有一点走弱了，这就要注意了。另外第二点 回踩完成之后，第二次上攻的时候成交量也要放大市场，这里面要给出强势状态，一旦这种符合的话， 那么就代表着已经确认了新的上涨行情已经开启了，这个时候就是我们进考虑呢继续加仓的这种动作。 所以综合来看的话，今天实际上要看这些细节，但不管怎么说，周末交易出来之后，包括在上周五我们 也讲了 ...

恒瑞医药 20251205 摘要 恒瑞医药坚持创新和国际化双轮驱动战略，聚焦肿瘤、代谢、心血管、 自免及退行性疾病等领域，通过技术创新和"借船出海"策略拓展国际 市场，自 2023 年以来已达成 12 笔对外许可交易，总金额近 280 亿美 元。 公司通过建立和迭代细胞治疗、核酸药物、基因治疗及蛋白降解剂等新 兴技术平台，并注重创新模块的基本功，组合成差异化的治疗方案，例 如在代谢领域开发 PCSK9 抑制剂和长效小分子疗法。 恒瑞医药在肿瘤治疗领域构建四位一体的协同创新疗法，包括免疫治疗 （PD-1、细胞因子、细胞治疗）、靶向化疗（ADC、多肽-核素连接）、 支持治疗和精准治疗（KRAS 抑制剂），并探索融合不同技术平台以实 现更高效的肿瘤免疫反应。 在代谢疾病领域，恒瑞已有多个糖尿病口服产品上市，并计划于 2026 年推出减重药 9,531，该产品临床数据显示出良好的疗效和安全性，公 司正致力于解决现有减重药的副作用和依从性问题，并研究新型给药方 式。 Q&A 恒瑞医药未来的发展战略是什么？ 恒瑞医药近年来在研发投入和国际化方面取得了哪些成就？ 截至目前，恒瑞医药累计投入研发费用已超过 500 亿人民币， ...

全球格局重构与"十五五"战略新机遇 - 2026 年资本市 场年度策略展望 20251207 摘要 Q&A 2026 年资本市场的年度策略展望是什么？ 2026 年资本市场的年度策略展望主要从多个维度进行分析，包括美联储全球 流动性、中美关系、国内政策方向和科技发展等方面。首先，美联储的宽松政 策是否超预期是关键因素。如果只是被动宽松，即每次降息或宽松幅度低于市 场预期，这种宽松对市场影响有限。只有当美联储进入主动宽松阶段，才会对 市场产生正面影响。从现在到 2026 年底，即鲍威尔被换掉之前，美联储整体 处于被动宽松状态，很难进入主动宽松。 在 12 月即将举行的一期会议中，美 联储可能会选择降息 25 个基点，但明年的点阵图可能相对鹰派，或者不降息 但给出较鸽派的点阵图。特朗普可能在 12 月底或 1 月份提前宣布下届美联储 主席名单，如塞特，这将引发一波流动性宽松预期，对国内外股票尤其是科技 股有利。然而，这种预期只能持续一两个月，因为新任主席上任前不会发表过 多言论，而鲍威尔则可能更为鹰派。 全球科技股方面，尽管波动加大，但没有 2026 年科技方面重点配置围绕 AI 及其应用层面的相关产业，包括 A ...

Core Viewpoint - The National Healthcare Security Administration (NHSA) has announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and introduces the Commercial Health Insurance Innovative Drug Catalog for 2025, marking the eighth adjustment since the NHSA's establishment and the first addition of a commercial insurance catalog [1][2]. Group 1: Drug Catalog Adjustments - A total of 114 new drugs have been added to the national medical insurance catalog, including 50 Class 1 innovative drugs, while 29 drugs have been removed due to lack of clinical supply or better alternatives [2]. - The new catalog includes drugs addressing significant diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as treatments for rare diseases and chronic conditions like diabetes and autoimmune diseases [2]. - The overall success rate for the newly added innovative drugs is 88%, an increase from 76% in 2024 [2]. Group 2: Market Impact and Growth Potential - The inclusion of innovative drugs in the insurance catalog is expected to lead to rapid revenue growth for these drugs, benefiting patients and driving growth for related pharmaceutical companies [3]. - Zhongtai Securities predicts that the innovative drug market will continue to thrive, noting that the current market conditions have returned to a relatively reasonable and low position, enhancing investment safety margins and return values [3]. Group 3: Company Announcements - Green Leaf Pharmaceutical has successfully included five new products in the national medical insurance and commercial health insurance catalogs, including MiMeiXin and ZhanBiJia [4]. - Fuhong Hanlin announced that its product Fuzhining has been included in the national medical insurance catalog for 2025 [5]. - Innovent Biologics reported that seven of its innovative products have been successfully added to the new national medical insurance catalog, including the PD-1 monoclonal antibody drug [6].

Core Insights - The company 奥赛康 (002755.SZ) announced that its product 利厄替尼片 (brand name: 奥壹新) has been included in the National Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog for 2025, as per the notification from the National Healthcare Security Administration and the Ministry of Human Resources and Social Security dated December 7, 2025 [1] Group 1 - 利厄替尼 is a third-generation EGFR TKI developed collaboratively by the Shanghai Institute of Materia Medica, the Guangzhou Institute of Biomedicine and Health, and 江苏奥赛康药业有限公司, specifically targeting EGFR mutation non-small cell lung cancer (NSCLC) [1] - The inclusion of 利厄替尼片 in the national medical insurance catalog is expected to enhance the product's accessibility, facilitating market promotion and positively impacting sales [1]

12月5日，金融监管总局发布《关于调整保险公司相关业务风险因子的通知》，在下调险企业务风险因 子的同时明确相关监管要求。一是对长期持仓的沪深300等指数成份股、科创板股票下调风险因子；二 是降低出口信用与海外投资保险的保费和准备金风险因子，同时要求险企完善内控、强化偿付能力管 理，且明确新规优先适用。 登录新浪财经APP 搜索【信披】查看更多考评等级 宏观热点 事关节能降碳工作！国常会最新部署 12月5日，国务院常务会议研究进一步做好节能降碳工作；听取规范涉企行政执法专项行动情况汇报并 审议通过《行政执法监督条例（草案）》；讨论《中华人民共和国国家消防救援人员法（草案）》；部 署全链条打击涉烟违法活动有关举措。会议指出，节能降碳是推进碳达峰碳中和、加快发展方式绿色转 型的重要抓手。要更高水平、更高质量做好节能降碳工作。要切实增强节能降碳内生动力，充分发挥政 策效应，不断完善市场机制。 吴清周末发声：适度打开资本空间和杠杆限制 12月6日，证监会主席吴清出席了中国证券业协会第八次会员大会，围绕证券行业高质量发展致辞。有 观点认为，本次吴清的发言传递出"国家兴衰，金融有责"的核心导向，其中"功能发挥"作为关键抓手 ...

三季报显示，汇添富香港优势精选混合A/C坚守投资主线、沿着以下方向布局：1）创新药：产品有全球竞争力和成长空间的pharma和biotech；2）进口 替代率低，壁垒高的优秀设备耗材龙头。 截至三季度末，汇添富香港优势精选混合A/C前十大重仓股分别为映恩生物、科伦博泰生、信达生物、三生制药、康诺亚、石药集团、恒瑞医药、诺诚 健华、荣昌生物、复宏汉霖。该基金的现任基金经理为张韡。张韡曾任东方证券医药助理研究员，汇添富基金医药研究员、高级医药研究员及医药行业研究 组组长。 同时，有9只QDII基金前11月涨幅超过87%，其中易方达基金管理有限公司旗下产品占4只，易方达全球医药行业混合(QDII)C(美元现汇份额)、易方达 全球医药行业混合(QDII)A(美元现汇份额)、易方达全球医药行业混合(QDII)C(人民币份额)、易方达全球医药行业混合(QDII)A(人民币份额)均涨超92%。 截至三季度末，上述4只基金前十大重仓股分别为复宏汉霖、信达生物、科伦博泰生、映恩生物、乐普生物、康诺亚、中国生物制药、翰森制药、三生 制、荣昌生物。 4只基金目前由基金经理杨桢霄管理，杨桢霄现任易方达基金管理有限公司基金经理。曾任易 ...

Core Insights - The National Healthcare Security Administration (NHSA) has officially announced the latest version of the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, which includes 114 new drugs and 19 drugs in the first version of the Commercial Health Insurance Innovative Drug Catalog, effective from January 1, 2026 [1][2][3] Industry Summary - The NHSA has adjusted the drug catalog for the eighth time since its establishment, with a total of 949 new drugs added over the years, and the medical insurance fund has spent over 4.6 trillion RMB on negotiated drugs, driving sales exceeding 6 trillion RMB [1][2] - The new catalog includes 50 first-class innovative drugs, with an overall success rate of 88%, significantly higher than the 76% in 2024 [3] - The inclusion of drugs for major diseases such as triple-negative breast cancer, pancreatic cancer, and lung cancer, as well as rare diseases and chronic conditions, addresses gaps in basic medical insurance coverage [2][3] Company-Specific Updates - Green Leaf Pharmaceutical has successfully included five new products in the NHSA's drug catalog, including MiMeiXin® and ZhanBiJia® [4] - Fuhong Hanlin announced that its product Fuzhuoning® has been included in the NHSA's drug catalog for specific indications [5] - Junshi Biosciences reported that its products Tuoyi® and Junshida® have been successfully included in the NHSA's drug catalog [6] - Innovent Biologics has successfully added seven innovative products to the new NHSA drug catalog, including Daboru® and Xindimian® [6]

Core Insights - The 2025 Innovation Drug High-Quality Development Conference was held in Guangzhou, announcing the new drug directories for national basic medical insurance and commercial health insurance [1] Group 1: Drug Directory Adjustments - A total of 114 new drugs were added to the directory, including 50 first-class innovative drugs [2][6] - The first version of the commercial health insurance innovative drug directory includes 19 drugs, featuring CAR-T therapies for tumors, treatments for rare diseases like neuroblastoma and Gaucher disease, and Alzheimer's disease medications [2][4] Group 2: Complementarity of Insurance Directories - The commercial health insurance innovative drug directory is designed to complement the basic medical insurance, focusing on high-innovation drugs with significant clinical value that exceed basic insurance coverage [4] - The directory aims to clarify the boundaries of basic medical insurance and promote the development of a multi-tiered medical security system [4] Group 3: Financial Implications for Patients - The inclusion of CAR-T therapies, which can cost around 1.2 million yuan per treatment, is expected to significantly reduce out-of-pocket expenses for patients, potentially saving them hundreds of thousands of yuan [5] Group 4: Implementation Timeline - The new drug directory adjustments will be officially implemented nationwide on January 1, 2026, marking the eighth adjustment since the establishment of the National Medical Insurance Administration [6][7]